614 results on '"Leuzy, Antoine"'
Search Results
2. [18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
3. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
4. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease
5. The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
6. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
7. The impact of demographic, clinical, genetic, and imaging variables on tau PET status
8. A multicentre validation study of the diagnostic value of plasma neurofilament light.
9. Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
10. Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
11. Implementation and Assessment of Tau Thresholds in Non-Demented Individuals as Predictors of Cognitive Decline in Tau Imaging Studies.
12. Correction to: The Strategic Biomarker Roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
13. PET Biomarkers for Tau Pathology
14. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
15. Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
16. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
17. Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
18. Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
19. Biofluid phospho‐tau with subthreshold tau‐PET predicts higher rates of tau accumulation: implications for secondary prevention trials
20. Tau‐PET to predict conversion from mild cognitive impairment to dementia; a head‐to‐head comparison against amyloid‐PET and MRI
21. A CenTauR scale based on 18F‐MK6240
22. Towards a standardized pipeline for tau PET analysis under a GAAIN/LONI and CPAD collaborative framework
23. Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK‐6240
24. Detection of PART in vivo using tau‐PET: preliminary findings using [18F]RO948
25. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
26. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
27. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
28. Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
29. Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimerʼs disease
30. Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
31. Disturbances in brain energy metabolism in insulin resistance and diabetes and Alzheimer's disease — Learnings from brain imaging biomarkers
32. PET Biomarkers for Tau Pathology
33. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease
34. Tau PET imaging in neurodegenerative tauopathies—still a challenge
35. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis
36. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
37. Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
38. Quantitative positron emission tomography in brain research
39. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
40. Harmonization of tau‐PET in Alzheimer's disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK‐6240.
41. The implications of different approaches to define AT(N) in Alzheimer disease
42. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
43. Endocannabinoid System Biomarkers in Alzheimer's Disease
44. Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes
45. Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
46. CenTauR: Toward a universal scale and masks for standardizing tau imaging studies.
47. [18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
48. Comparison of group‐level and individualized ROIs for predicting change in longitudinal tau‐PET in preclinical and prodromal AD
49. CenTauRz: A standardized quantification of tau PET scans
50. A biomarker profile of elevated CSF p‐tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.